Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arecor TherapeuticsLSE:AREC +0.58%26 Days Payable is 173.89 as of Jun. 2025, which is 68% below its 10-year median of 540.57. GuruFocus rates LSE:AREC with a GF Score™ of 26/100 and a GF Value™ of £0.40 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 707 Biotechnology companies, Arecor Therapeutics ranks better than 85.71% on this metric.
The historical rank and industry rank for Arecor Therapeutics's Days Payable or its related term are showing as below:
LSE:AREC'
s Days Payable Range Over the Past 10 Years
Min: 217.27 Med: 540.57 Max: 949.43
Current: 949.43
During the past 6 years, Arecor Therapeutics's highest Days Payable was 949.43. The lowest was 217.27. And the median was 540.57.
LSE:AREC's Days Payable is ranked better than 85.71% of 707
companies
in the Biotechnology industry
Industry Median: 111.24
vs LSE:AREC: 949.43
Arecor Therapeutics's Days Payable
declined
from Jun. 2024 (359.14) to Jun. 2025 (173.89).
It may suggest that Arecor Therapeuticsaccelerated paying its suppliers.
The historical data trend for Arecor Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:AREC vs VRTX, REGN, MRNA: Days Payable Comparison
For the Biotechnology subindustry, Arecor Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arecor Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arecor Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Arecor Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Arecor Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arecor Therapeutics (LSE:AREC) has a Days Payable of 173.89 as of Jun. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Arecor Therapeutics and its competitors. This is 68% below median its historical median of 540.57. Over the past decade, Arecor Therapeutics' Days Payable has ranged from 217.27 to 949.43. According to the industry distribution chart, Arecor Therapeutics ranks #101 out of 707 companies in the Biotechnology industry, placing it in the top 14.3%.
Is Arecor Therapeutics' Days Payable too high?
Arecor Therapeutics' current Days Payable of 173.89 is 68% below median its 10-year median of 540.57. Over the past 10 years, this metric has ranged from a low of 217.27 to a high of 949.43. The Biotechnology industry median Days Payable is 111.24. Arecor Therapeutics' value of 173.89 is 56.3% above this industry median. Based on the distribution chart, Arecor Therapeutics ranks #101 out of 707 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Arecor Therapeutics has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arecor Therapeutics' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arecor Therapeutics ranks #101 out of 707 companies for Days Payable. This places Arecor Therapeutics in the top 14% of its industry — outperforming the majority of peers. The industry median Days Payable is 111.24. Arecor Therapeutics' value of 173.89 is 56.3% above this benchmark. Historically, Arecor Therapeutics' own Days Payable has ranged from 217.27 to 949.43 over the past decade. While the company's 10-year median is 540.57 vs. the industry median of 111.24, Arecor Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 111.24, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Arecor Therapeutics's current Days Payable of 173.89 is 56.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Arecor Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 111.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arecor Therapeutics's current Days Payable is 173.89, which is 68% below median its own 10-year median of 540.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arecor Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Arecor Therapeutics (LSE:AREC) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.40, compared to a current price of £0.86 — trading 115% above its estimated fair value. The current Days Payable is 173.89, which is 68% below median its 10-year median of 540.57 and 56.3% above the Biotechnology industry median of 111.24. Arecor Therapeutics' overall GF Score™ is 26/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Arecor Therapeutics (LSE:AREC), the current Days Payable is 173.89 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arecor Therapeutics (LSE:AREC) Overvalued in 2026?
Based on GuruFocus' analysis, Arecor Therapeutics stock appears to be overvalued.
The current stock price of £0.86 is trading 115% above its estimated GF Value™ of £0.40.
GuruFocus considers Arecor Therapeutics to be Significantly Overvalued.
Key valuation signals for LSE:AREC:
Days Payable: 173.89 (68% below median its 10-year median of 540.57)
GF Value™: £0.40 vs. price of £0.86 (115% above fair value)
Industry Position: 56.3% above the Biotechnology median (#101 of 707)
No single metric tells the full story. See the LSE:AREC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing medicines to market through the enhancement of existing therapeutic products. By applying an proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Europe (excl. UK) & Middle East, and the USA, out of which the majority is from the Europe (excl. UK) & Middle East.
26GF Score
Get the complete analysis for LSE:AREC
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:AREC has been successfully added to your 
